scholarly journals Hyaluronic acid-tagged silica nanoparticles in colon cancer therapy: therapeutic efficacy evaluation

2015 ◽  
pp. 6445 ◽  
Author(s):  
Zhi-Jun Huo ◽  
Kai Liu ◽  
Zhi-qi Wang ◽  
Shi-jiang Wang ◽  
Ping Liu ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Hyaluronic Acid ◽  
Cancer Therapy ◽  
Silica Nanoparticles ◽  
Therapeutic Efficacy ◽  
Efficacy Evaluation

scholarly journals pH-operated hybrid silica nanoparticles with multiple H-bond stoppers for colon cancer therapy

RSC Advances ◽  
2015 ◽  
Vol 5 (80) ◽  
pp. 64932-64936 ◽  
Author(s):  
C. Théron ◽  
A. Gallud ◽  
S. Giret ◽  
M. Maynadier ◽  
D. Grégoire ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Therapy ◽  
Silica Nanoparticles ◽  
Cancer Cells ◽  
Cyanuric Acid ◽  
Carcinoma Cells ◽  
Controlled Delivery ◽  
Chemotherapeutic Drug ◽  
Colon Carcinoma Cells ◽  
Hybrid Silica

Controlled delivery of a chemotherapeutic drug from pH-sensitive hybrid silica nanocarriers efficiently targets colon carcinoma cells. The drug, blocked by cyanuric acid as stopper, is autonomously released inside the cancer cells.

scholarly journals TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism

2021 ◽  
Vol 9 (2) ◽  
pp. e001798
Author(s):  
Stefania Canè ◽  
Jacques Van Snick ◽  
Catherine Uyttenhove ◽  
Luc Pilotte ◽  
Benoit J Van den Eynde
Keyword(s):  
Colon Cancer ◽  
T Cells ◽  
Cancer Therapy ◽  
Therapeutic Efficacy ◽  
Transforming Growth Factor ◽  
Single Agent ◽  
Cardiovascular Development ◽  
Cardiovascular Toxicity ◽  
Mesenchymal Transition ◽  
Melanoma Model

BackgroundTransforming growth factor-β (TGFβ) is emerging as a promising target for cancer therapy, given its ability to promote progression of advanced tumors and to suppress anti-tumor immune responses. However, TGFβ also plays multiple roles in normal tissues, particularly during organogenesis, raising toxicity concerns about TGFβ blockade. Dose-limiting cardiovascular toxicity was observed, possibly due to the blockade of all three TGFβ isoforms. The dominant isoform in tumors is TGFβ1, while TGFβ2 and TGFβ3 seem to be more involved in cardiovascular development. Recent data indicated that selective targeting of TGFβ1 promoted the efficacy of checkpoint inhibitor anti-PD1 in transplanted preclinical tumor models, without cardiovascular toxicity.MethodsTo further explore the therapeutic potential of isoform-specific TGFβ blockade, we developed neutralizing mAbs targeting mature TGFβ1 or TGFβ3, and tested them, in parallel with anti-panTGFβ mAb 1D11, in two preclinical models: the transplanted colon cancer model CT26, and the autochthonous melanoma model TiRP.ResultsWe observed that the blockade of TGFβ1, but not that of TGFβ3, increased the efficacy of a prophylactic cellular vaccine against colon cancer CT26. This effect was similar to pan-TGFβ blockade, and was associated with increased infiltration of activated CD8 T cells in the tumor, and reduced levels of regulatory T cells and myeloid-derived suppressor cells. In contrast, in the autochthonous TiRP melanoma model, we observed therapeutic efficacy of the TGFβ1-specific mAb as a single agent, while the TGFβ3 mAb was inactive. In this model, the anti-tumor effect of TGFβ1 blockade was tumor intrinsic rather than immune mediated, as it was also observed in T-cell depleted mice. Mechanistically, TGFβ1 blockade increased mouse survival by delaying the phenotype switch, akin to epithelial-to-mesenchymal transition (EMT), which transforms initially pigmented tumors into highly aggressive unpigmented tumors.ConclusionsOur results confirm TGFβ1 as the relevant isoform to target for cancer therapy, not only in combination with checkpoint inhibitors, but also with other immunotherapies such as cancer vaccines. Moreover, TGFβ1 blockade can also act as a monotherapy, through a tumor-intrinsic effect blocking the EMT-like transition. Because human melanomas that resist therapy often express a gene signature that links TGFβ1 with EMT-related genes, these results support the clinical development of TGFβ1-specific mAbs in melanoma.

Tumor-targeted docetaxel-loaded hyaluronic acid-quercetin polymeric micelles with p-gp inhibitory property for hepatic cancer therapy

RSC Advances ◽  
2016 ◽  
Vol 6 (33) ◽  
pp. 27542-27556 ◽  
Author(s):  
Chenfeng Xu ◽  
Yu Ding ◽  
Jiang Ni ◽  
Lifang Yin ◽  
Jianping Zhou ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Hyaluronic Acid ◽  
Cancer Therapy ◽  
Targeted Drug Delivery ◽  
Therapeutic Efficacy ◽  
Polymeric Micelles ◽  
Hepatic Cancer ◽  
Efflux Inhibition ◽  
Targeted Drug

Herein, a novel targeted drug delivery nanosystem based on hyaluronic acid (HA) and quercetin (QU) was designed to improve the in vivo therapeutic efficacy of DTX on HC through HA-CD44 mediated targeting and QU-based p-gp efflux inhibition.

Hyaluronic acid–conjugated silica nanoparticles for breast cancer therapy

2016 ◽  
Vol 47 (5) ◽  
pp. 777-782 ◽  
Author(s):  
Jinmao Li ◽  
Xiaojun Yang ◽  
Ping Yang ◽  
Fangning Gao
Keyword(s):  
Breast Cancer ◽  
Hyaluronic Acid ◽  
Cancer Therapy ◽  
Silica Nanoparticles ◽  
Breast Cancer Therapy
Sign in / Sign up

Export Citation Format

Share Document